248 related articles for article (PubMed ID: 29325301)
1. [Role of CD36 in nonalcoholic fatty liver disease].
Zhan Z; Ren H; Peng ML
Zhonghua Gan Zang Bing Za Zhi; 2017 Dec; 25(12):953-956. PubMed ID: 29325301
[TBL] [Abstract][Full Text] [Related]
2. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?
Rada P; González-Rodríguez Á; García-Monzón C; Valverde ÁM
Cell Death Dis; 2020 Sep; 11(9):802. PubMed ID: 32978374
[TBL] [Abstract][Full Text] [Related]
3. [Research advances in the pathogenesis of non-alcoholic fatty liver disease-associated liver cancer].
Huang W; Zhang XX
Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):157-160. PubMed ID: 28297806
[TBL] [Abstract][Full Text] [Related]
4. Biological Mechanisms and Related Natural Inhibitors of CD36 in Nonalcoholic Fatty Liver.
Feng Y; Sun W; Sun F; Yin G; Liang P; Chen S; Liu X; Jiang T; Zhang F
Drug Des Devel Ther; 2022; 16():3829-3845. PubMed ID: 36388082
[TBL] [Abstract][Full Text] [Related]
5. Circulating sCD36 levels in patients with non-alcoholic fatty liver disease and controls.
Heebøll S; Poulsen MK; Ornstrup MJ; Kjær TN; Pedersen SB; Nielsen S; Grønbæk H; Handberg A
Int J Obes (Lond); 2017 Feb; 41(2):262-267. PubMed ID: 27916988
[TBL] [Abstract][Full Text] [Related]
6. Transcription factor SOX2 contributes to nonalcoholic fatty liver disease development by regulating the expression of the fatty acid transporter CD36.
Shen C; Chen JH; Oh HR; Park JH
FEBS Lett; 2021 Oct; 595(19):2493-2503. PubMed ID: 34536973
[TBL] [Abstract][Full Text] [Related]
7. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
8. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Chow MD; Lee YH; Guo GL
Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
[TBL] [Abstract][Full Text] [Related]
9. [Role of probiotics in treatment of nonalcoholic fatty liver disease].
Chen M; Wang MC; Ni R; Wang J; Wang L; Wang GN; Zhang LY
Zhonghua Gan Zang Bing Za Zhi; 2017 Jan; 25(1):77-80. PubMed ID: 28297790
[TBL] [Abstract][Full Text] [Related]
10. Dietary sucrose regulates the expression of the Cd36 gene in hepatic tissue of rats with obesity and Non Alcoholic Fatty Liver Disease (NAFLD).
Castro RQ; Soto Rodriguez I; Deschamps Lago RA; Pagola PG; Rodriguez Antolin J; Peres Quintal A; Rivera JR; Aguilera AA
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Jun; 162(2):99-106. PubMed ID: 29765172
[TBL] [Abstract][Full Text] [Related]
11. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk.
Ballestri S; Nascimbeni F; Baldelli E; Marrazzo A; Romagnoli D; Lonardo A
Adv Ther; 2017 Jun; 34(6):1291-1326. PubMed ID: 28526997
[TBL] [Abstract][Full Text] [Related]
12. Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease.
Jiang ZG; Tapper EB; Connelly MA; Pimentel CF; Feldbrügge L; Kim M; Krawczyk S; Afdhal N; Robson SC; Herman MA; Otvos JD; Mukamal KJ; Lai M
Liver Int; 2016 Aug; 36(8):1213-20. PubMed ID: 26815314
[TBL] [Abstract][Full Text] [Related]
13. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
[TBL] [Abstract][Full Text] [Related]
14. [Research advances in diagnosis of non-alcoholic fatty liver disease].
Wang JH; Yu CH
Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):115-118. PubMed ID: 28297797
[TBL] [Abstract][Full Text] [Related]
15. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
Barritt AS; Gitlin N; Klein S; Lok AS; Loomba R; Malahias L; Powell M; Vos MB; Weiss LM; Cusi K; Neuschwander-Tetri BA; Sanyal A
Contemp Clin Trials; 2017 Oct; 61():33-38. PubMed ID: 28735109
[TBL] [Abstract][Full Text] [Related]
16. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic Steatohepatitis: Histopathology Basics Within a Broader Context.
Schild MH; Guy CD
Surg Pathol Clin; 2018 Jun; 11(2):267-285. PubMed ID: 29751874
[TBL] [Abstract][Full Text] [Related]
19. miRNAs in non-alcoholic fatty liver disease.
He Z; Hu C; Jia W
Front Med; 2016 Dec; 10(4):389-396. PubMed ID: 27680976
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World.
Sayiner M; Koenig A; Henry L; Younossi ZM
Clin Liver Dis; 2016 May; 20(2):205-14. PubMed ID: 27063264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
